Key result
In patients without inducible sustained VT postablation, inducible nonsustained VT was independently associated with a higher risk of VT recurrence (HR 3.66; 95% CI 1.3-11.1).
Why the study?
Does inducible nonsustained VT postablation predict VT recurrence in patients with ischemic cardiomyopathy undergoing ablation for SMVT?
Cohort (n=165)
Does inducible nonsustained VT postablation predict VT recurrence in patients with ischemic cardiomyopathy undergoing ablation for SMVT?
Hazard Ratio: 3.66 (95% CI 1.3–11.1)
Absolute Event Rate: 45% vs 60%
p-value: p=0.017
Inducible nonsustained VT after ablation for SMVT in ischemic cardiomyopathy is an independent predictor of VT recurrence, indicating the continued presence of functional arrhythmia substrate.
May support postablation inducibility testing for risk stratification; leaves open whether targeting nonsustained VT improves outcomes.
Background Noninducibility of sustained monomorphic ventricular tachycardia (SMVT) postablation does not insure absence of later recurrence in patients with ischemic cardiomyopathy. This study aims to determine the relation between inducible nonsustained VT postablation and VT recurrences. Methods and Results One hundred sixty-five consecutive patients (156 male; age 68±9 years) underwent ablation for SMVT because of ischemic cardiomyopathy; 44 patients who did not have induction testing or in whom only ventricular fibrillation was induced after ablation were excluded. In 38 patients (23%), SMVT was inducible (group C). Of the 83 patients without inducible SMVT after ablation, nonsustained VT defined as ≥5 beats lasting for <30 s, was induced in 34 patients (group B, 21%), whereas the remaining 49 patients had no VT induced by the induction test (group A, 30%). Over a median follow-up of 18.7 months, freedom from recurrent VT at 24 months was 60% in group A, 45% in group B ( P =0.017 versus group A), and 38% in group C ( P =0.005 versus group A). In patients without inducible SMVT, inducible nonsustained VT and left ventricular ejection fraction was independently associated with VT recurrence (hazard ratio, 3.66 and 1.07; 95% CI, 1.3–11.1 and 1.01–1.14). Conclusions Inducible nonsustained VT postablation suggests the continued presence of functional arrhythmia substrate. Further trials are needed to assess whether additional ablation would improve outcome in this group.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2017) conducted a cohort in Ischemic cardiomyopathy with sustained monomorphic ventricular tachycardia (n=165). Inducible nonsustained ventricular tachycardia postablation vs. No inducible ventricular tachycardia postablation was evaluated on Freedom from recurrent VT at 24 months (HR 3.66, 95% CI 1.3-11.1, p=0.017). In patients without inducible sustained VT postablation, inducible nonsustained VT was independently associated with a higher risk of VT recurrence (HR 3.66; 95% CI 1.3-11.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: